NASDAQ:ONVO

Organovo Competitors

$8.41
-0.31 (-3.56 %)
(As of 04/16/2021 04:00 PM ET)
Add
Compare
Today's Range
$8.31
Now: $8.41
$8.90
50-Day Range
$8.67
MA: $10.51
$13.32
52-Week Range
$5.80
Now: $8.41
$23.92
Volume135,833 shs
Average Volume341,809 shs
Market Capitalization$59.85 million
P/E RatioN/A
Dividend YieldN/A
Beta0.85

Competitors

Organovo (NASDAQ:ONVO) Vs. INMB, ADMA, LOGC, GMDA, GNFT, and TARA

Should you be buying ONVO stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Organovo, including INmune Bio (INMB), ADMA Biologics (ADMA), LogicBio Therapeutics (LOGC), Gamida Cell (GMDA), Genfit (GNFT), and Protara Therapeutics (TARA).

INmune Bio (NASDAQ:INMB) and Organovo (NASDAQ:ONVO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, institutional ownership, analyst recommendations and profitability.

Institutional & Insider Ownership

7.4% of INmune Bio shares are owned by institutional investors. Comparatively, 48.7% of Organovo shares are owned by institutional investors. 58.9% of INmune Bio shares are owned by insiders. Comparatively, 5.1% of Organovo shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

INmune Bio has a beta of 3.01, meaning that its share price is 201% more volatile than the S&P 500. Comparatively, Organovo has a beta of 0.85, meaning that its share price is 15% less volatile than the S&P 500.

Profitability

This table compares INmune Bio and Organovo's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
INmune BioN/A-41.18%-39.34%
OrganovoN/A-71.01%-67.22%

Valuation & Earnings

This table compares INmune Bio and Organovo's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
INmune BioN/AN/A$-7,680,000.00($0.75)-18.16
Organovo$2.20 million27.21$-18,710,000.00N/AN/A

INmune Bio has higher earnings, but lower revenue than Organovo.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for INmune Bio and Organovo, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
INmune Bio00403.00
Organovo0000N/A

INmune Bio currently has a consensus price target of $19.25, suggesting a potential upside of 41.34%. Given INmune Bio's higher probable upside, equities analysts clearly believe INmune Bio is more favorable than Organovo.

Summary

INmune Bio beats Organovo on 7 of the 9 factors compared between the two stocks.

ADMA Biologics (NASDAQ:ADMA) and Organovo (NASDAQ:ONVO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, analyst recommendations, profitability and institutional ownership.

Profitability

This table compares ADMA Biologics and Organovo's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ADMA Biologics-166.01%-98.83%-37.21%
OrganovoN/A-71.01%-67.22%

Analyst Ratings

This is a summary of current ratings and price targets for ADMA Biologics and Organovo, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ADMA Biologics00503.00
Organovo0000N/A

ADMA Biologics currently has a consensus target price of $7.80, indicating a potential upside of 372.73%. Given ADMA Biologics' higher probable upside, equities analysts plainly believe ADMA Biologics is more favorable than Organovo.

Insider and Institutional Ownership

48.9% of ADMA Biologics shares are held by institutional investors. Comparatively, 48.7% of Organovo shares are held by institutional investors. 11.7% of ADMA Biologics shares are held by company insiders. Comparatively, 5.1% of Organovo shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares ADMA Biologics and Organovo's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ADMA Biologics$29.35 million6.82$-48,280,000.00($0.92)-1.79
Organovo$2.20 million27.21$-18,710,000.00N/AN/A

Organovo has lower revenue, but higher earnings than ADMA Biologics.

Risk and Volatility

ADMA Biologics has a beta of 1.84, indicating that its stock price is 84% more volatile than the S&P 500. Comparatively, Organovo has a beta of 0.85, indicating that its stock price is 15% less volatile than the S&P 500.

Summary

ADMA Biologics beats Organovo on 7 of the 11 factors compared between the two stocks.

LogicBio Therapeutics (NASDAQ:LOGC) and Organovo (NASDAQ:ONVO) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends.

Institutional and Insider Ownership

33.8% of LogicBio Therapeutics shares are owned by institutional investors. Comparatively, 48.7% of Organovo shares are owned by institutional investors. 23.4% of LogicBio Therapeutics shares are owned by company insiders. Comparatively, 5.1% of Organovo shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares LogicBio Therapeutics and Organovo's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
LogicBio TherapeuticsN/A-117.64%-76.85%
OrganovoN/A-71.01%-67.22%

Risk & Volatility

LogicBio Therapeutics has a beta of 1.34, indicating that its stock price is 34% more volatile than the S&P 500. Comparatively, Organovo has a beta of 0.85, indicating that its stock price is 15% less volatile than the S&P 500.

Valuation & Earnings

This table compares LogicBio Therapeutics and Organovo's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LogicBio TherapeuticsN/AN/A$-40,130,000.00($1.78)-3.30
Organovo$2.20 million27.21$-18,710,000.00N/AN/A

Organovo has higher revenue and earnings than LogicBio Therapeutics.

Analyst Ratings

This is a summary of current recommendations for LogicBio Therapeutics and Organovo, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
LogicBio Therapeutics00303.00
Organovo0000N/A

LogicBio Therapeutics currently has a consensus target price of $18.50, indicating a potential upside of 214.63%. Given LogicBio Therapeutics' higher possible upside, analysts plainly believe LogicBio Therapeutics is more favorable than Organovo.

Summary

Organovo beats LogicBio Therapeutics on 5 of the 9 factors compared between the two stocks.

Gamida Cell (NASDAQ:GMDA) and Organovo (NASDAQ:ONVO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, earnings, profitability, analyst recommendations, institutional ownership and valuation.

Risk and Volatility

Gamida Cell has a beta of 2.03, meaning that its share price is 103% more volatile than the S&P 500. Comparatively, Organovo has a beta of 0.85, meaning that its share price is 15% less volatile than the S&P 500.

Insider & Institutional Ownership

48.7% of Organovo shares are held by institutional investors. 5.1% of Organovo shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Gamida Cell and Organovo's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gamida CellN/AN/A$-34,350,000.00($1.69)-4.53
Organovo$2.20 million27.21$-18,710,000.00N/AN/A

Organovo has higher revenue and earnings than Gamida Cell.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Gamida Cell and Organovo, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gamida Cell00503.00
Organovo0000N/A

Gamida Cell presently has a consensus target price of $20.25, indicating a potential upside of 164.71%. Given Gamida Cell's higher probable upside, equities research analysts plainly believe Gamida Cell is more favorable than Organovo.

Profitability

This table compares Gamida Cell and Organovo's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Gamida CellN/A-112.47%-65.09%
OrganovoN/A-71.01%-67.22%

Summary

Organovo beats Gamida Cell on 5 of the 9 factors compared between the two stocks.

Organovo (NASDAQ:ONVO) and Genfit (NASDAQ:GNFT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, earnings, risk, valuation and dividends.

Analyst Ratings

This is a summary of current recommendations and price targets for Organovo and Genfit, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Organovo0000N/A
Genfit32502.20

Genfit has a consensus target price of $43.60, suggesting a potential upside of 911.60%. Given Genfit's higher probable upside, analysts plainly believe Genfit is more favorable than Organovo.

Volatility and Risk

Organovo has a beta of 0.85, suggesting that its share price is 15% less volatile than the S&P 500. Comparatively, Genfit has a beta of 1.33, suggesting that its share price is 33% more volatile than the S&P 500.

Valuation & Earnings

This table compares Organovo and Genfit's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Organovo$2.20 million27.21$-18,710,000.00N/AN/A
Genfit$45.88 million3.94$-72,960,000.00($1.97)-2.19

Organovo has higher earnings, but lower revenue than Genfit.

Profitability

This table compares Organovo and Genfit's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
OrganovoN/A-71.01%-67.22%
GenfitN/AN/AN/A

Insider & Institutional Ownership

48.7% of Organovo shares are owned by institutional investors. Comparatively, 0.4% of Genfit shares are owned by institutional investors. 5.1% of Organovo shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Genfit beats Organovo on 6 of the 10 factors compared between the two stocks.

Organovo (NASDAQ:ONVO) and Protara Therapeutics (NASDAQ:TARA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, profitability, valuation, dividends and earnings.

Volatility & Risk

Organovo has a beta of 0.85, suggesting that its stock price is 15% less volatile than the S&P 500. Comparatively, Protara Therapeutics has a beta of 1.17, suggesting that its stock price is 17% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Organovo and Protara Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Organovo0000N/A
Protara Therapeutics00303.00

Protara Therapeutics has a consensus target price of $47.6667, suggesting a potential upside of 201.31%. Given Protara Therapeutics' higher possible upside, analysts plainly believe Protara Therapeutics is more favorable than Organovo.

Institutional and Insider Ownership

48.7% of Organovo shares are owned by institutional investors. Comparatively, 83.1% of Protara Therapeutics shares are owned by institutional investors. 5.1% of Organovo shares are owned by company insiders. Comparatively, 45.7% of Protara Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Organovo and Protara Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Organovo$2.20 million27.21$-18,710,000.00N/AN/A
Protara TherapeuticsN/AN/A$-14,990,000.00N/AN/A

Protara Therapeutics has lower revenue, but higher earnings than Organovo.

Profitability

This table compares Organovo and Protara Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
OrganovoN/A-71.01%-67.22%
Protara TherapeuticsN/A-45.45%-41.09%

Summary

Protara Therapeutics beats Organovo on 8 of the 9 factors compared between the two stocks.


Organovo Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
INmune Bio logo
INMB
INmune Bio
1.5$13.62-20.9%$203.39 millionN/A-14.04
ADMA Biologics logo
ADMA
ADMA Biologics
1.6$1.65-4.8%$200.10 million$29.35 million-1.92
LogicBio Therapeutics logo
LOGC
LogicBio Therapeutics
1.3$5.88-5.8%$188.31 millionN/A-3.67
Gamida Cell logo
GMDA
Gamida Cell
1.4$7.65-2.2%$185.28 millionN/A-5.35
Genfit logo
GNFT
Genfit
1.3$4.31-2.6%$180.70 million$45.88 million-2.19News Coverage
Protara Therapeutics logo
TARA
Protara Therapeutics
1.8$15.82-1.4%$177.64 millionN/A0.00Increase in Short Interest
Voyager Therapeutics logo
VYGR
Voyager Therapeutics
1.7$4.56-3.5%$171.70 million$104.39 million-2.78
Applied Genetic Technologies logo
AGTC
Applied Genetic Technologies
1.5$3.99-1.3%$170.58 million$2.45 million-1.87Gap Up
Fennec Pharmaceuticals logo
FENC
Fennec Pharmaceuticals
1.5$6.27-2.6%$163.04 millionN/A-7.65
Axcella Health logo
AXLA
Axcella Health
1.6$4.25-0.2%$160.18 millionN/A-1.98
X4 Pharmaceuticals logo
XFOR
X4 Pharmaceuticals
1.8$9.01-3.2%$156.63 millionN/A-2.82
Champions Oncology logo
CSBR
Champions Oncology
1.8$11.06-2.1%$148.09 million$32.12 million-85.08Analyst Upgrade
News Coverage
ERYTECH Pharma logo
ERYP
ERYTECH Pharma
0.5$6.91-3.6%$146.40 millionN/A-1.76News Coverage
Gap Up
Checkmate Pharmaceuticals logo
CMPI
Checkmate Pharmaceuticals
2.0$6.67-5.8%$144.19 millionN/A0.00Increase in Short Interest
News Coverage
Dyadic International logo
DYAI
Dyadic International
1.3$5.01-1.6%$138.05 million$1.68 million-14.74Increase in Short Interest
Pluristem Therapeutics logo
PSTI
Pluristem Therapeutics
1.4$4.34-0.0%$137.75 million$20,000.000.00News Coverage
Ayala Pharmaceuticals logo
AYLA
Ayala Pharmaceuticals
1.4$10.45-0.5%$137.63 million$2.33 million0.00
Aziyo Biologics logo
AZYO
Aziyo Biologics
1.4$12.90-0.6%$131.92 millionN/A0.00Gap Down
TRACON Pharmaceuticals logo
TCON
TRACON Pharmaceuticals
1.7$8.06-3.1%$124.76 million$3 million-2.59Analyst Upgrade
Gap Down
Genocea Biosciences logo
GNCA
Genocea Biosciences
1.6$2.21-4.5%$118.28 millionN/A-1.52Analyst Report
Brainstorm Cell Therapeutics logo
BCLI
Brainstorm Cell Therapeutics
1.3$3.13-2.6%$111.81 millionN/A-2.98
La Jolla Pharmaceutical logo
LJPC
La Jolla Pharmaceutical
1.7$4.07-2.7%$111.63 million$23.05 million-1.81
PolarityTE logo
PTE
PolarityTE
1.4$0.88-2.3%$106.45 million$5.65 million-0.53Increase in Short Interest
Cidara Therapeutics logo
CDTX
Cidara Therapeutics
1.6$2.14-1.9%$102.81 million$20.92 million-1.23
AIM ImmunoTech logo
AIM
AIM ImmunoTech
1.7$2.10-0.5%$100.43 million$140,000.000.00
Kiromic BioPharma logo
KRBP
Kiromic BioPharma
1.0$9.34-0.5%$68.49 millionN/A0.00Lockup Expiration
BioCardia logo
BCDA
BioCardia
1.5$3.98-3.5%$65.03 million$710,000.00-2.05Analyst Downgrade
Increase in Short Interest
Allena Pharmaceuticals logo
ALNA
Allena Pharmaceuticals
1.3$1.12-1.8%$63.77 millionN/A-0.89Gap Up
aTyr Pharma logo
LIFE
aTyr Pharma
1.5$3.77-1.9%$60.36 million$420,000.00-1.42Increase in Short Interest
GENE
Genetic Technologies
0.4$3.87-0.8%$58.16 million$10,000.000.00Gap Down
Brickell Biotech logo
BBI
Brickell Biotech
1.5$0.84-0.0%$56.50 million$7.92 million-0.35News Coverage
Windtree Therapeutics logo
WINT
Windtree Therapeutics
2.3$2.14-1.9%$56.19 million$200,000.00-0.89Decrease in Short Interest
Microbot Medical logo
MBOT
Microbot Medical
1.3$7.55-2.3%$53.67 millionN/A0.00Decrease in Short Interest
Idera Pharmaceuticals logo
IDRA
Idera Pharmaceuticals
1.8$1.10-1.8%$46.48 million$1.45 million-0.39Increase in Short Interest
Acorda Therapeutics logo
ACOR
Acorda Therapeutics
1.4$4.19-6.2%$39.76 million$192.41 million0.76News Coverage
BiondVax Pharmaceuticals logo
BVXV
BiondVax Pharmaceuticals
0.5$3.09-2.3%$35.08 millionN/A-1.02Decrease in Short Interest
News Coverage
ENTX
Entera Bio
1.2$3.00-10.0%$34.29 million$240,000.00-4.41
Seneca Biopharma logo
SNCA
Seneca Biopharma
0.5$1.39-2.2%$24.04 million$10,000.000.00Increase in Short Interest
Titan Pharmaceuticals logo
TTNP
Titan Pharmaceuticals
1.2$2.29-0.0%$22.59 million$3.61 million-0.31
This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.